Records of 2 325 patients with CHD were extracted from 20 hostpial information systems, who were divided into two groups, one group has 768 patients using Dengzhan Xixin, the other group has 1 557 patients without using Dengzhan Xixin. Using generalized boosted models (GBM) with propensity scores to balance confounding factors and using three Logistic regressions to analysis the cure rates of coronary heart disease. The results is that 72 knowing confounding factors between two groups, such as: age, admission condition, dying days, regression coefficients of three Logistic regressions were negative (P < 0.05), statistically, the result of using Dengzhan Xixin injection to cure coronary heart disease is significantly higher than do not using Dengzhan Xixin injection. Propensity score could be a good method to balance confounding factors in a retrospective data analysis. However it is not a prospective research, the information from this study should be carefully referred to.
Download full-text PDF |
Source |
---|
Zhongguo Zhong Yao Za Zhi
October 2022
Gansu University of Chinese Medicine Lanzhou 730000, China Affiliated Hospital of Gansu University of Chinese Medicine Lanzhou 730000, China.
This study aims to systematically evaluate the efficacy and safety of Chinese medicine injections in the treatment of rheumatoid arthritis. Specifically, randomized controlled trial(RCT) in the treatment of rheumatoid arthritis with Chinese medicine injections was retrieved from PubMed, EMbase, Cochrane Library, Web of Science, Wanfang, CNKI, VIP, and SinoMed(from inception to February 16, 2022). RevMan 5.
View Article and Find Full Text PDFFront Pharmacol
August 2022
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Acute ischemic stroke (AIS) is a common cause of death and long-term disability worldwide. Recent trials of platelet-activating factor receptor antagonists (PAFRA) appeared to indicate that they could play a neuroprotective role in the treatment of AIS; therefore, we conducted a systematic literature review to evaluate the clinical efficacy and safety of PAFRA in patients with AIS. A systematic literature search was performed in seven electronic databases from inception to 11 March 2022.
View Article and Find Full Text PDFJ Ethnopharmacol
April 2022
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China; Ethnic Medicine Academic Heritage Innovation Research Center, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China; Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China. Electronic address:
Ethnopharmacological Relevance: Dengzhan Xixin injection (DX), a preparation of extracts from traditional Chinese medicine Erigeron breviscapus (Vaniot) Hand.-Mazz., has been widely used in clinical treatment of cerebral ischemia sequelae in China for a long history.
View Article and Find Full Text PDFZhongguo Zhong Yao Za Zhi
July 2021
Institute of Basic Medicine,Xiyuan Hospital,Chinese Academy of Chinese Medical Sciences Beijing 100091, China National Clinical Research Center of Cardiovascular Disease of Traditional Chinese Medicine Beijing 100091,China.
The present study evaluated the curative efficacy of Chinese herbal injection on unstable angina pectoris( UAP) by network Meta-analysis. The databases,including Pub Med,Cochrane Library,Web of Science,CNKI,CBM,VIP and Wanfang were searched for randomized controlled trial( RCT) of Chinese herbal injection in the treatment of UAP. All researchers independently screened the articles,extracted the data and evaluated the quality.
View Article and Find Full Text PDFChem Pharm Bull (Tokyo)
April 2021
Department of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University.
Dengzhan Xixin injection (DZXXI), a herbal product prepared from a Chinese herb called Erigeron breviscapus, is a classical and traditional therapeutic for cadiovascular diseases (CVDs), including coronary heart disease (CHD), angina, and stroke, etc. However, its potential pharmacology mechanism against CVDs remains unclear. In this paper, a systems pharmacology-based strategy is presented for predicting drug targets and understanding therapeutic mechanisms of DZXXI against CVDs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!